Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission.

Clinical and experimental medicine·2025
Same author

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.

Frontiers in immunology·2023
Same author

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.

Journal of hematology & oncology·2023
Same author

Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.

Annals of hematology·2021
Same author

Improving risk stratification of patients with childhood acute lymphoblastic leukemia: Glutathione-S-Transferases polymorphisms are associated with increased risk of relapse.

Oncotarget·2016
Same author

Myelodysplastic syndromes in South America: a multinational study of 1080 patients.

American journal of hematology·2015

Related Experiment Video

Updated: Apr 19, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.9K

[IgE myeloma. Laboratory typing difficulties].

Nora S Bovone1, María Cristina Fuente, Ana María Gastiazoro

  • 1Servicio de Bioquímica, Laboratorio de Proteínas, Hospital Nacional Alejandro Posadas, Buenos Aires, Argentina.

Medicina
|January 3, 2015
PubMed
Summary

IgE multiple myeloma is a rare and aggressive plasma cell cancer. Laboratory challenges in diagnosing this condition can lead to incorrect results, highlighting the need for careful analysis.

Keywords:
clinical laboratorymonoclonal componentmyeloma

More Related Videos

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

12.5K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Related Experiment Videos

Last Updated: Apr 19, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.9K
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

12.5K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Area of Science:

  • Hematology
  • Oncology

Background:

  • IgE multiple myeloma is an exceptionally rare plasma cell neoplasm, representing only 0.01% of all plasma cell dyscrasias.
  • Fewer than 50 cases are documented in medical literature, underscoring its rarity and aggressive nature.

Observation:

  • This case report details a patient diagnosed with IgE myeloma.
  • The study highlights significant laboratory difficulties encountered during the diagnostic process.

Findings:

  • Accurate classification of the monoclonal component in serum and urine is crucial for diagnosing multiple myeloma subtypes.
  • The specific challenges associated with IgE myeloma diagnosis can potentially result in erroneous laboratory reports.

Implications:

  • Emphasizes the critical role of meticulous laboratory investigation in diagnosing rare hematological malignancies.
  • Suggests a need for improved diagnostic protocols or awareness regarding IgE myeloma to prevent misdiagnosis.